France Pancreatic Cancer Treatment Market

France Pancreatic Cancer Treatment Market Insights Forecasts to 2035

• The France Pancreatic Cancer Treatment Market Size Was Estimated at USD 89.9 Million in 2024
• The France Pancreatic Cancer Treatment Market Size is Expected to Grow at a CAGR of Around 12.03% from 2025 to 2035
• The France Pancreatic Cancer Treatment Market Size is Expected to Reach USD 313.7 Million by 2035

 

 

According to a research report published by Decision Advisor, The France Pancreatic Cancer Treatment Market Size is Anticipated to reach USD 313.7 Million by 2035, Growing at a CAGR of 12.03% from 2025 to 2035. The France pancreatic cancer treatment market is driven by the rising incidence of pancreatic cancer, late-stage diagnosis requiring intensive therapies, and increasing adoption of advanced treatments such as targeted therapies and immunotherapy. Improving healthcare infrastructure and growing awareness and demand for personalized medicine further support market growth.

 

Market Overview

The France pancreatic cancer treatment market represents the portion of the pharmaceutical and healthcare sector that focuses on developing, manufacturing, and commercializing therapies for pancreatic cancer in France. The market includes chemotherapy, targeted therapies, immunotherapy, surgical interventions, and combination treatments, which aim to control disease progression, relieve symptoms, prolong survival, and enhance patient quality of life. These treatments are supplied to hospitals, oncology centers, specialized cancer clinics, and outpatient care facilities. The market is primarily driven by the increasing incidence of pancreatic cancer in the country, supported by healthcare initiatives, research advancements, and improved access to innovative therapies.

 

The France pancreatic cancer treatment market is driven by the rising incidence and high mortality of pancreatic cancer in the country. Approximately 16,000 new cases and 12,700 deaths are reported annually, primarily affecting men and women over 50. With a low 5-year survival rate of around 10–13%, there is a critical need for effective therapies, including chemotherapy, targeted therapy, immunotherapy, surgical interventions, and combination treatments. Hospitals, oncology centers, and outpatient clinics are the main channels delivering these treatments, addressing both disease progression and quality of life for patients.

 

Future growth of the France pancreatic cancer treatment market is supported by government-backed initiatives and research funding, such as the €1 million from Bpifrance (France 2030) for AI?based early detection and broader tens of millions in INCa and Fondation ARC funding for innovative therapies. Increasing awareness, improved diagnostics, and continuous R&D create opportunities for new treatments, making this market a high-potential segment within France’s healthcare and pharmaceutical industry.

 

Report Coverage

This research report categorizes the market for the France pancreatic cancer treatment market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France pancreatic cancer treatment market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France pancreatic cancer treatment market.

 

Driving Factors

The France pancreatic cancer treatment market is driven by the rising incidence of pancreatic cancer, high mortality rates, and an aging population, which create strong demand for effective therapies. Growth is further supported by advances in chemotherapy, targeted therapies, immunotherapy, and surgery, along with government funding such as €1 million from Bpifrance (France 2030) and broader INCa and Fondation ARC research support, increasing awareness, improved diagnostics, and access to specialized healthcare facilities.

 

Restraining Factors

The France pancreatic cancer treatment market is restrained by high treatment costs, late-stage diagnosis, and limited survival benefits, which can reduce adoption. Additionally, stringent regulatory approvals and the complexity or side effects of therapies may further hinder market growth.

 

Market Segmentation

The France pancreatic cancer treatment market share is classified into type and treatment.

• The exocrine segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France pancreatic cancer treatment market is segmented by type into exocrine and endocrine. Among these, the exocrine segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The exocrine segment is growing because most pancreatic cancer cases in France are exocrine, especially pancreatic ductal adenocarcinoma. Its aggressive nature and late diagnosis increase the demand for treatments like chemotherapy and targeted therapy, driving revenue growth.

 

• The chemotherapy segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France pancreatic cancer treatment market is segmented by treatment into chemotherapy and radiation therapy. Among these, the chemotherapy segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The chemotherapy segment is growing because it is the most widely used and effective treatment for pancreatic cancer in France, especially for advanced-stage cases. Its ability to slow disease progression, manage symptoms, and improve survival drives strong demand and market growth.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France pancreatic cancer treatment market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• AstraZeneca PLC
• Novartis AG
• Pfizer Inc.
• Genentech (Roche)
• Bristol?Myers Squibb Company
• Ipsen S.A.
• Erytech Pharma
• Sanofi S.A.
• Merck & Co., Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Oncodesign Precision Medicine (OPM)
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decision Advisor, has segmented the France pancreatic cancer treatment market based on the below-mentioned segments:

 

France Pancreatic Cancer Treatment Market, By Type

• Exocrine
• Endocrine

 

France Pancreatic Cancer Treatment Market, By Treatment

• Chemotherapy
• Radiation Therapy

 

FAQ’s

1. What is the France pancreatic cancer treatment market size in 2024?

The France pancreatic cancer treatment market size was estimated at USD 89.9 million in 2024.

 

2. What is the projected market size of the France pancreatic cancer treatment market by 2035?

The France pancreatic cancer treatment market size is expected to reach USD 313.7 million by 2035.

 

3. What is the CAGR of the France pancreatic cancer treatment market?

The France pancreatic cancer treatment market size is expected to grow at a CAGR of around 12.03% from 2024 to 2035.

 

4. What are the key growth drivers of the France pancreatic cancer treatment market?

The France pancreatic cancer treatment market is driven by the rising incidence of pancreatic cancer, late-stage diagnosis requiring intensive therapies, and increasing adoption of advanced treatments such as targeted therapies and immunotherapy. Improving healthcare infrastructure and growing awareness and demand for personalized medicine further support market growth.

 

5. Which treatment segment dominated the market in 2024?

The chemotherapy segment dominated the market in 2024.

 

6. What segments are covered in the France pancreatic cancer treatment market report?

The France pancreatic cancer treatment market is segmented on the basis of type and treatment.

 

7. Who are the key players in the France pancreatic cancer treatment market?

Key companies include AstraZeneca PLC, Novartis AG, Pfizer Inc., Genentech (Roche), Bristol?Myers Squibb Company, Ipsen S.A., Erytech Pharma, Sanofi S.A., Merck & Co., Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Oncodesign Precision Medicine (OPM), and others.

 

8. Who are the target audiences for this market report?

The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).